Concomitant therapies for first-line Helicobacter pylori eradication

Comparison of the efficacy of 10-day vs. 12-day concomitant therapies for first-line Helicobacter pylori eradication in Iran.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170521034070N2

Enrollment

200

Registered

2019-10-28

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Gastric ulcer. Condition 2: Duodenal ulcer. Gastric ulcer Duodenal ulcer

Interventions

Intervention 1: Patients in the intervention group will receive Pantoprazole 40 mg, Amoxicillin 1g, Clarithromycin 500 mg and Metronidazole 500 mg (all given twice daily) for ten days. Intervention 2:

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with peptic ulcer disease according to endoscopic findings Presence of Helicobacter pylori is proven in gastric tissue according to pathologic assessment of gastric biopsy No history of previous treatment for Helicobacter pylori

Exclusion criteria

Exclusion criteria: Breast feeding History of gastrointestinal surgery History of gastrointestinal malignancy using anticoagulant drugs using anti convulsion drugs pregnancy

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication. Timepoint: Eight weeks after receiving the drugs, Helicobacter pylori eradication will be evaluated by Urea Breath test. Method of measurement: Urea Breath test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Bari

Sari University of Medical Sciences

zohreb252@yahoo.com+98 11 3377 1760

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026